A series of bills were either passed or signed in the two states
days after the U.S. Supreme Court temporarily paused
implementation of lower court rulings that would have either
removed Food and Drug Administration approval for the abortion
drug mifepristone, or restricted its use.
The Vermont measure, which passed the legislature on Thursday,
would add abortion to the state's list of protected health care
services, meaning that doctors and pharmacists who provide the
medication to terminate a pregnancy would not be prosecuted.
In Washington, Governor Jay Inslee, a Democrat, on Thursday
signed five bills aimed at protecting abortion access, including
one authorizing the state Department of Corrections to acquire
and dispense abortion medications whether or not the patient is
in its custody. The bill allows the department to sell the drug
to clinics and providers who commit to using it for abortion
care or medical management of miscarriage.
The federal lawsuit in seeking to eliminate access to
mifepristone - in Texas by the anti-abortion group Alliance
Defending Freedom - was filed after last June's decision by the
Supreme Court to overturn Roe v. Wade, the 1973 case that
established a constitutional right to abortion nationwide.
After Judge Matthew Kacsmaryk, appointed by former U.S.
President Donald Trump, ruled in the group's favor earlier this
month, clinics and providers were thrown into chaos as they
grappled with how to proceed. An appeals court ruling soon
followed, keeping Kacsmaryk's order restricting mifepristone's
use in place but pausing his sweeping order to revoke it's FDA
approval.
States where abortion rights are protected scrambled to preserve
access to the drug. Several stockpiled mifepristone, while
others, including California, purchased supplies of misoprostol,
the second medication used in the regimen. Clinics plan to pivot
to using only misoprostol should access to mifepristone be
removed.
(Reporting by Sharon Bernstein, editing by Ross Colvin and Grant
McCool)
[© 2023 Thomson Reuters. All rights
reserved.]
Copyright 2022 Reuters. All rights reserved. This material may
not be published, broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|